Pharmaron Beijing Co Ltd

Pharmaron Beijing maintains a conservative capital structure with a debt-to-equity ratio of 0.65, indicating a balanced approach to leverage. The company holds CNY 4.57 billion in cash and equivalents, but this is offset by CNY 8.25 billion in long-term debt, resulting in a net cash position of negative CNY 3.68 billion. The current ratio of 2.52 suggests strong short-term liquidity, with current assets comfortably covering current liabilities. However, the liquidity risk remains medium due to the significant long-term debt burden relative to cash reserves.

Profitability metrics show a return on equity (ROE) of 1.82% and a return on assets (ROA) of 0.91%, both below the industry median for Biotechnology & Medical Research firms. The gross margin of 32.2% (CNY 859.3 million gross profit on CNY 2.67 billion revenue) is in line with industry norms, but the operating margin of 13.2% (CNY 351.7 million operating income) is slightly below the median, indicating potential inefficiencies in cost management. Net income of CNY 230.6 million reflects a net margin of 8.6%, which is modest for a contract research organization (CRO).

The company operates primarily in a single business segment focused on drug discovery and development services, with geographic exposure concentrated in China, where the majority of its revenue is generated. There is no disclosed diversification into other geographic regions or product lines, which increases revenue concentration risk.

Pharmaron Beijing reported revenue of CNY 2.67 billion in the latest period, with a year-over-year growth rate of 12.3%. Analysts project continued growth, with a mean price target of CNY 30.12 and a median of CNY 29.15, suggesting a positive outlook for the stock. The company's revenue trajectory is expected to benefit from increased demand for CRO services in the Asia-Pacific region.

Risk factors include the company's high leverage and the potential for dilution, although the risk of dilution is currently assessed as low. The company has not issued additional shares recently, and there is no indication of a pending equity offering. However, the negative net cash position could necessitate future financing, which may involve dilutive measures.

Recent events include the release of the latest financial results, which showed a slight decline in net income compared to the prior year. The company has not disclosed any major strategic shifts or new product launches in the most recent filings. Analysts remain cautiously optimistic, with a mean recommendation of 1.64 (on a scale of 1 to 5) and no "hold" or "sell" ratings.

Revenue grew 14.8% year-over-year to CNY 14.1 billion, demonstrating strong top-line expansion momentum.

Analysts project 94.5% upside to a mean price target of CNY 30.13, signaling significant undervaluation.

The company faces high credit risk, posing potential challenges for debt servicing and financial stability.

Debt-to-equity ratio of 0.65 is in the bottom quartile, indicating higher leverage than most peers.

Revenue ¥3.64B, +13,4% YoY; Operating income +23,4% YoY.

• ▍Revenue ¥3.64B, +13,4% YoY
• ▍Operating income +23,4% YoY
• ▍Net income +42,5% YoY
• ▍Net margin 12.1%

Revenue ¥3.46B; Operating income ¥589.1M.

• ▍Revenue ¥3.46B
• ▍Operating income ¥589.1M
• ▍Net margin 10.7%

Revenue ¥3.21B; Operating income ¥473.7M.

• ▍Revenue ¥3.21B
• ▍Operating income ¥473.7M
• ▍Net margin 9.6%

Revenue ¥2.93B; Operating income ¥1.04B.

• ▍Revenue ¥2.93B
• ▍Operating income ¥1.04B
• ▍Net margin 30.1%

Revenue ¥2.67B; Operating income ¥351.7M.

• ▍Revenue ¥2.67B
• ▍Operating income ¥351.7M
• ▍Net margin 8.6%

Revenue ¥14.10B, +14,8% YoY; Operating income −8,8% YoY.

• ▍Revenue ¥14.10B, +14,8% YoY
• ▍Operating income −8,8% YoY
• ▍Net income −7,2% YoY
• ▍Free cash flow −142,3% YoY
• ▍Net margin 11.8%

Revenue ¥12.28B, +6,4% YoY; Operating income +21,6% YoY.

• ▍Revenue ¥12.28B, +6,4% YoY
• ▍Operating income +21,6% YoY
• ▍Net income +12,0% YoY
• ▍Free cash flow +173,5% YoY
• ▍Net margin 14.6%

Revenue ¥11.54B, +12,4% YoY; Operating income +8,3% YoY.

• ▍Revenue ¥11.54B, +12,4% YoY
• ▍Operating income +8,3% YoY
• ▍Net income +16,5% YoY
• ▍Free cash flow +46,7% YoY
• ▍Net margin 13.9%

Revenue ¥10.27B, +37,9% YoY; Operating income −2,8% YoY.

• ▍Revenue ¥10.27B, +37,9% YoY
• ▍Operating income −2,8% YoY
• ▍Net income −17,2% YoY
• ▍Free cash flow −791,9% YoY
• ▍Net margin 13.4%

Revenue ¥7.44B; Operating income ¥1.92B.

• ▍Revenue ¥7.44B
• ▍Operating income ¥1.92B
• ▍Net margin 22.3%